Mazdutide and ecnoglutide join the GLP-1 watchlist as Chinese candidates draw attention

Chinese-origin GLP-1 candidates are now part of the standing industry watchlist in the United States, with mazdutide and ecnoglutide tracked for approvals and data alongside the American and European programs that have dominated the field ^[1]. High-dose mazdutide results were among the data featured at the American Diabetes Association's 2026 scientific sessions ^[2].

Mazdutide is a dual glucagon and GLP-1 receptor agonist that is approved for weight management in China ^[2]. In the GLORY-2 trial, researchers tested a 9 mg subcutaneous dose for 60 weeks in 461 adults in China with overweight or obesity, 16% of whom had type 2 diabetes. The average body mass index was 34 ^[2].

Participants assigned to the 9 mg dose had a placebo-subtracted weight loss of 15.1%, according to Rita Kalyani, MD, the ADA's chief scientific and medical officer, who discussed the trial on a JAMA Medical News podcast. The trial also showed significant reductions in systolic blood pressure, triglycerides and non-HDL cholesterol ^[2]. The results were presented in an oral session and published in JAMA ^[2].

Kalyani said studying these drugs in an Asian population, where the burden of diabetes is high, helps show how generalizable the results are and whether subpopulations differ in the benefits they see ^[2]. The podcast was published in June 2026 and covered the ADA sessions in New Orleans ^[2].

The August 2026 obesity drug news log lists mazdutide and ecnoglutide among "China-origin agonists" on its standing watchlist, tracked for approvals and data ^[1]. Ecnoglutide is named only as a tracked candidate; no trial results, approval dates or US filing plans for it have been reported ^[1].

The same log follows the wider field: semaglutide and tirzepatide for new indications and outcomes data; orforglipron, CagriSema and retatrutide for regulatory progress; and MariTide for extended-dosing data. Next-wave candidates include zenagamtide, formerly known as amycretin, along with survodutide and pemvidutide ^[1].

Why it matters for patients

Approval in China does not create access in the United States. Neither mazdutide nor ecnoglutide has been approved by the US Food and Drug Administration, and no US filing has been reported for either ^[1]. The medicines already available in the US — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and the oral drug orforglipron (Foundayo), which the FDA approved for obesity in April 2026 ^[1] — are unaffected by the addition of Chinese candidates to watchlists.

Trial results also carry limits. GLORY-2 enrolled adults in China, and Kalyani framed the value of that data partly as a question of generalizability rather than proof that the same results would appear in other populations ^[2]. Weight-loss percentages are not comparable across trials of different lengths, and this trial ran 60 weeks ^[2]. Whether either drug will be tested in US patients, and on what timeline, has not been reported ^[1].

Unapproved versions of these medicines are a separate safety concern. The August log notes that illicit supply remained a live issue and that Eli Lilly has brought six US lawsuits against sellers of unapproved retatrutide, which is still investigational ^[1]. Those lawsuits concern retatrutide, not mazdutide or ecnoglutide; no similar litigation involving those two has been reported ^[1].

What happens next

No near-term US milestones for mazdutide or ecnoglutide have been disclosed ^[1]. The dated events in the current log involve other drugs. Oral arguments in Lilly's appeal against the FDA over retatrutide's application type are set for 24 September 2026. The National Institute for Health and Care Excellence appraisal of orforglipron carries an expected publication date of 18 November 2026. A CagriSema FDA decision is expected in late 2026, Lilly has targeted the first quarter of 2027 for its retatrutide submission, and further TRIUMPH readouts are expected before the end of the year ^[1].